Literature DB >> 7550854

Serum pepsinogen in screening for gastric cancer.

A Kodoi1, M Yoshihara, K Sumii, K Haruma, G Kajiyama.   

Abstract

To establish a sensitive and efficient screening method for gastric cancer using serum pepsinogen, we investigated the characteristics of serum pepsinogen I and II levels and the I/II ratio and their cut-off points. We found that the pepsinogen I level and the I/II ratio were significantly lower in patients with gastric cancer than in control subjects, especially in patients with cancers of the differentiated type, the elevated type, and the depressed type without ulceration. However, sex, depth of invasion, and location of tumor did not correlate with the pepsinogen levels. A suitable cut-off point in screening for gastric cancer was a pepsinogen I level of less than 50 ng/ml and a I/II ratio of less than 3.0, as determined by receiver operator characteristics curves. The sensitivity, the specificity, and the accuracy of detection for all types of gastric cancer were approximately 55%, 75%, and 72%, respectively. If restricted to cancers of the elevated and the depressed type without ulceration, the sensitivity was approximately 85%, and the specificity and accuracy were approximately 76% and 77%, respectively. These results suggest that, in screening for gastric cancer when using pepsinogen levels and morphological examinations, the suitable cut-off point in regard to specificity is as stated above. However, regarding sensitivity, when the pepsinogen method is used alone, a pepsinogen I level of less than 70 ng/ml and a I/II ratio of less than 3.0 is acceptable.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7550854     DOI: 10.1007/bf02347560

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  12 in total

1.  [Estimation of frequency, population doses and stochastic risks in stomach mass screening examinations in Japan, 1980].

Authors:  T Maruyama; Y Noda; Y Kumamoto; K Nishizawa; Y Furuya; K Iwai; S Urahashi; R Kurihara; R Kamata; S Sakata
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  1987-07-25

2.  Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence.

Authors:  I M Samloff
Journal:  Gastroenterology       Date:  1971-08       Impact factor: 22.682

3.  UICC workshop of the Project on Evaluation of Screening Programmes for Gastrointestinal Cancer.

Authors:  J Chamberlain; N E Day; M Hakama; A B Miller; P C Prorok
Journal:  Int J Cancer       Date:  1986-03-15       Impact factor: 7.396

4.  Correlation between the prevalence of gastritis and gastric cancer in Japan.

Authors:  A Fukao; S Hisamichi; N Ohsato; N Fujino; N Endo; M Iha
Journal:  Cancer Causes Control       Date:  1993-01       Impact factor: 2.506

5.  Chronic atrophic gastritis in a population at risk for gastric carcinoma.

Authors:  K Jaskiewicz; H D Louwrens
Journal:  Anticancer Res       Date:  1991 Mar-Apr       Impact factor: 2.480

6.  Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders.

Authors:  M Ichinose; K Miki; C Furihata; T Kageyama; R Hayashi; H Niwa; H Oka; T Matsushima; K Takahashi
Journal:  Clin Chim Acta       Date:  1982-12-09       Impact factor: 3.786

7.  [A clinical study of pepsinogen I and II producing gastric carcinomas].

Authors:  A Kodoi; K Haruma; M Yoshihara; T Shimamoto; C Watanabe; S Okamoto; H Kawaguchi; A Tari; K Sumii; G Kajiyama
Journal:  Nihon Shokakibyo Gakkai Zasshi       Date:  1993-12

8.  [Studies on pepsinogen production in advanced gastric cancer tissue].

Authors:  T Saito
Journal:  Nihon Geka Gakkai Zasshi       Date:  1989-08

9.  Clinical application of serum pepsinogen I and II levels for mass screening to detect gastric cancer.

Authors:  K Miki; M Ichinose; K B Ishikawa; N Yahagi; M Matsushima; N Kakei; S Tsukada; M Kido; S Ishihama; Y Shimizu
Journal:  Jpn J Cancer Res       Date:  1993-10

10.  Atrophic gastritis and stomach cancer risk: cross-sectional analyses.

Authors:  I Kato; S Tominaga; Y Ito; S Kobayashi; Y Yoshii; A Matsuura; A Kameya; T Kano
Journal:  Jpn J Cancer Res       Date:  1992-10
View more
  21 in total

1.  Accuracy of screening for gastric cancer using serum pepsinogen concentrations.

Authors:  F Kitahara; K Kobayashi; T Sato; Y Kojima; T Araki; M A Fujino
Journal:  Gut       Date:  1999-05       Impact factor: 23.059

2.  Strategy for eliminating gastric cancer in Japan.

Authors:  Masahiro Asaka; Mototsugu Kato; David Y Graham
Journal:  Helicobacter       Date:  2010-12       Impact factor: 5.753

3.  Gastric cancer screening using the serum pepsinogen test method.

Authors:  Kazumasa Miki
Journal:  Gastric Cancer       Date:  2006-11-24       Impact factor: 7.370

4.  The correlation of endoscopic and histological diagnosis of gastric atrophy.

Authors:  Alisher Eshmuratov; Jong Chun Nah; Nayoung Kim; Hye Seung Lee; Hee Eun Lee; Byoung Hwan Lee; Min Sik Uhm; Young Soo Park; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2009-07-23       Impact factor: 3.199

5.  Validation of the pepsinogen test method for gastric cancer screening using a follow-up study.

Authors:  Shigeto Mizuno; Masao Kobayashi; Shohken Tomita; Ikuya Miki; Atsuhiro Masuda; Mitsuko Onoyama; Yasuki Habu; Hideto Inokuchi; Yoshiyuki Watanabe
Journal:  Gastric Cancer       Date:  2009-11-05       Impact factor: 7.370

6.  Novel risk markers for gastric cancer screening: Present status and future prospects.

Authors:  Shotaro Enomoto; Takao Maekita; Hiroshi Ohata; Kimihiko Yanaoka; Masashi Oka; Masao Ichinose
Journal:  World J Gastrointest Endosc       Date:  2010-12-16

7.  Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED).

Authors:  M Dinis-Ribeiro; M Areia; A C de Vries; R Marcos-Pinto; M Monteiro-Soares; A O'Connor; C Pereira; P Pimentel-Nunes; R Correia; A Ensari; J M Dumonceau; J C Machado; G Macedo; P Malfertheiner; T Matysiak-Budnik; F Megraud; K Miki; C O'Morain; R M Peek; T Ponchon; A Ristimaki; B Rembacken; F Carneiro; E J Kuipers
Journal:  Virchows Arch       Date:  2011-12-22       Impact factor: 4.064

8.  Evaluation of gastric cancer risk using topography of histological gastritis: a large-scaled cross-sectional study.

Authors:  Shinobu Imagawa; Masaharu Yoshihara; Masanori Ito; Shigeto Yoshida; Yoshihiro Wada; Masana Tatsugami; Akemi Takamura; Shinji Tanaka; Ken Haruma; Kazuaki Chayama
Journal:  Dig Dis Sci       Date:  2007-11-13       Impact factor: 3.199

9.  Atrophic gastritis, but not antibody to Helicobacter pylori, is associated with body mass index in a Japanese population.

Authors:  Takehiro Torisu; Takayuki Matsumoto; Yutaka Takata; Toshihiro Ansai; Inho Soh; Shuji Awano; Ikuo Nakamichi; Shuntaro Kagiyama; Kazuo Sonoki; Akihiro Yoshida; Tomoko Hamasaki; Mitsuo Iida; Tadamichi Takehara
Journal:  J Gastroenterol       Date:  2008-10-29       Impact factor: 7.527

10.  Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis.

Authors:  Yoshihisa Urita; Kazuo Hike; Naotaka Torii; Yoshinori Kikuchi; Eiko Kanda; Masahiko Sasajima; Kazumasa Miki
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.